Candid to Acquire Rallybio in Reverse Merger, Taking Company Public

Why It Matters

The merger provides Candid with immediate market access and capital to accelerate its bispecific antibody program, while offering Rallybio shareholders exposure to a differentiated, clinical‑stage portfolio poised to reshape autoimmune therapy.

Key Takeaways

• Candid raises $505M, fueling T‑cell engager pipeline.
• Reverse merger lists Candid as CDRX on NYSE.
• cizutamig targets BCMA/CD3, entering Phase 2 this year.
• Rallybio shares jump from $2 to ~$10 post‑announcement.
• Bispecific antibodies expand from oncology to autoimmune therapies.

Pulse Analysis

The reverse merger between Candid Therapeutics and Rallybio illustrates a growing preference for capital‑light public listings among late‑stage biotech firms. By absorbing Rallybio’s public shell, Candid sidesteps the lengthy traditional IPO process while instantly gaining a market‑visible platform under the ticker CDRX. The transaction is underpinned by a $505 million private financing round that attracted more than a dozen venture and institutional investors, signaling strong confidence in Candid’s bispecific antibody platform. For Rallybio, the deal offers a lifeline after a turbulent 2024‑25 period marked by workforce cuts and a collapsing share price.

Candid’s lead candidate, cizutamig, is a bispecific T‑cell engager that bridges BCMA on B‑cells with CD3 on T‑cells, a mechanism originally explored in oncology but now repurposed for autoimmune disorders such as myasthenia gravis and interstitial lung disease. By directing a patient’s own T‑cells to eliminate pathogenic B‑cells, the therapy promises the efficacy of cellular treatments with the simplicity of an injectable drug. Early pre‑clinical data suggest a favorable safety profile, and the upcoming Phase 2 trial will be a critical barometer for the broader applicability of bispecifics beyond cancer.

The market reacted positively, lifting Rallybio’s share price from a $2 trough to nearly $10, reflecting investor optimism that the combined entity will unlock value through a differentiated pipeline. If cizutamig and other candidates such as CND261 succeed, Candid could become a template for biotech firms leveraging bispecific technology to address high‑unmet‑need indications. Moreover, the deal underscores a broader industry trend where capital‑rich private rounds and reverse mergers are reshaping how innovative therapeutics reach public markets, potentially accelerating drug development timelines.

Deal Summary

Candid Therapeutics announced a reverse merger with Rallybio, creating a publicly traded company under the Candid name and ticker CDRX. The boards of both companies approved the transaction, which is expected to close in mid‑2026. The deal includes a $505 million private financing from venture‑capital firms to fund the combined entity.